Press Releases | Alexion Pharmaceuticals, Inc

About Alexion
Patient Focus
Products
Research & Development
Responsibility
Careers
Select a Country
- North America
  - Canada
  - USA
- Latin America
  - Argentina
  - Brazil
  - Colombia
  - Mexico
- Europe, the Middle East & Africa
  - Alexion Europe
  - Belgium
  - Denmark
  - France
  - Germany
  - Ireland
  - Italy
  - Netherlands
  - Norway
  - Russia
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - UAE
  - UK
- Asia Pacific
  - Australia
  - China
  - India
  - Japan
Investors
News
Contact

Home
»
Newsroom
»
Press Releases

Press Releases

All News Releases

Alexion to Report Third Quarter 2018 Results on Wednesday, October 24, 2018
October 4, 2018
HTML PDF
Alexion to Acquire Syntimmune
September 26, 2018
HTML PDF
Alexion to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology
September 25, 2018
HTML PDF
Alexion Announces Successful Phase 3 PREVENT Study of Soliris® (Eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
September 24, 2018
HTML PDF
Alexion to Present at Morgan Stanley’s 16th Annual Global Healthcare Conference
September 7, 2018
HTML PDF
Alexion to Present at Citi’s 13th Annual Biotech Conference
August 29, 2018
HTML PDF
FDA Accepts Priority Review of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the US
August 20, 2018
HTML PDF
Alexion Reports Second Quarter 2018 Results
July 26, 2018
HTML PDF
Alexion to Report Second Quarter 2018 Results on Thursday, July 26, 2018
June 28, 2018
HTML PDF
Alexion Submits Application for Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the European Union (EU)
June 28, 2018
HTML PDF